Literature DB >> 30843785

Oral streptococci show diversity in resistance to complement immunity.

Lívia A Alves1, Thaís R de Carli1, Erika N Harth-Chu1, Flávia S Mariano1, José F Höfling1, Rafael N Stipp1, Renata O Mattos-Graner1.   

Abstract

PURPOSE: Mechanisms underlying systemic infections by oral species of Mitis (Streptococcus mitis, Streptococcus oralis) and Sanguinis (Streptococcus gordonii, Streptococcus sanguinis) commensal streptococci are poorly understood. This study investigates profiles of susceptibility to complement-mediated host immunity in representative strains of these four species, which were isolated from oral sites or from the bloodstream.
METHODOLOGY: Deposition of complement opsonins (C3b/iC3b), and surface binding to C-reactive protein (CRP) and to IgG antibodies were quantified by flow cytometry in 34 strains treated with human serum (HS), and compared to rates of opsonophagocytosis by human PMN mediated by complement (CR1/3) and/or IgG Fc (FcγRII/III) receptors.
RESULTS: S. sanguinis strains showed reduced susceptibility to complement opsonization and low binding to CRP and to IgG compared to other species. Surface levels of C3b/iC3b in S. sanguinis strains were 4.5- and 7.8-fold lower than that observed in S. gordonii and Mitis strains, respectively. Diversity in C3b/iC3b deposition was evident among Mitis species, in which C3b/iC3b deposition was significantly associated with CR/FcγR-dependent opsonophagocytosis by PMN (P<0.05). Importantly, S. gordonii and Mitis group strains isolated from systemic infections showed resistance to complement opsonization when compared to oral isolates of the respective species (P<0.05).
CONCLUSIONS: This study establishes species-specific profiles of susceptibility to complement immunity in Mitis and Sanguinis streptococci, and indicates that strains associated with systemic infections have increased capacity to evade complement immunity. These findings highlight the need for studies identifying molecular functions involved in complement evasion in oral streptococci.

Entities:  

Keywords:  bacteremiae; complement system; infective endocarditis; phagocytosis; systemic virulence; viridans streptococci

Mesh:

Substances:

Year:  2019        PMID: 30843785     DOI: 10.1099/jmm.0.000955

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

1.  Synergism between Corynebacterium and Streptococcus sanguinis reveals new interactions between oral commensals.

Authors:  Puthayalai Treerat; Ulrike Redanz; Sylvio Redanz; Rodrigo A Giacaman; Justin Merritt; Jens Kreth
Journal:  ISME J       Date:  2020-02-04       Impact factor: 10.302

2.  PepO is a target of the two-component systems VicRK and CovR required for systemic virulence of Streptococcus mutans.

Authors:  Lívia A Alves; Tridib Ganguly; Érika N Harth-Chú; Jessica Kajfasz; José A Lemos; Jacqueline Abranches; Renata O Mattos-Graner
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

3.  PcsB Expression Diversity Influences on Streptococcus mitis Phenotypes Associated With Host Persistence and Virulence.

Authors:  Erika N Harth-Chu; Lívia A Alves; Jéssica D Theobaldo; Mariana F Salomão; José F Höfling; William F King; Daniel J Smith; Renata O Mattos-Graner
Journal:  Front Microbiol       Date:  2019-11-12       Impact factor: 5.640

4.  Bacterial-Specific Induction of Inflammatory Cytokines Significantly Decreases upon Dual Species Infections of Implant Materials with Periodontal Pathogens in a Mouse Model.

Authors:  Muhammad Imran Rahim; Andreas Winkel; Alexandra Ingendoh-Tsakmakidis; Stefan Lienenklaus; Christine S Falk; Michael Eisenburger; Meike Stiesch
Journal:  Biomedicines       Date:  2022-01-26

5.  Diversity in Phenotypes Associated With Host Persistence and Systemic Virulence in Streptococcus sanguinis Strains.

Authors:  Livia A Alves; Geovanny C Salvatierra; Victor A Freitas; José F Höfling; Débora C Bastos; Thaís L S Araujo; Renata O Mattos-Graner
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.